CLR 131: Interim Phase I data

Interim data from 5 patients with relapsed or refractory MM in the first cohort of an open-label, dose-escalation, U.S. Phase I trial showed that a single dose of 12.5 mCi/m 2 IV CLR 131 led to stable...